Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Recurrence-free survival (RFS) Arm B vs Arm C

RFS (per RECIST 1.1 criteria as assessed by BICR) will be defined as the time from the date of randomization until the date of the first objective radiologic recurrence or death due to any cause, whichever occurs first.

Time frame: Up to 49 months after first patient randomized

Overall Survival (OS) for Arm A vs Arm C and Arm B vs Arm C

OS is defined as the time from the date of randomization until death due to any cause

Time frame: No timeframe

Recurrence-free survival at 24 months (RFS24) and 36 months (RFS36) for Arm A vs Arm C and Arm B vs Arm C

Proportion of RFS at 24 months and at 36 months

Time frame: At 24 and at 36 months

Time to recurrence (TTR) for Arm A vs Arm C and Arm B vs Arm C

TTR is defined as the time from the date of randomization until the date of disease recurrence

Time frame: Up to 49 months after first patient randomized

Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C

Time from randomization to recurrence/progression on next therapy (RFS2/PFS2)

Time frame: Up to 49 months after first patient randomized